Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 12/20 | 0.55 |
| ▸ | BACE1 | P56817 | 2/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | CCKAR | P32238 | 2/20 | 0.45 |
| ▸ | CCKBR | P32239 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157759 | 0.97 | OPRD1 (0.52) | OPRD1BACE1BACE2OPRM1OPRK1 | |
| SCHEMBL3366840 | 0.92 | CASP1 (0.51) | OPRD1BACE1BACE2 | |
| SCHEMBL2332848 | 0.84 | OPRM1 (0.47) | OPRD1BACE1BACE2OPRM1OPRK1 | |
| SCHEMBL5614017 | 0.83 | MAOB (0.41) | BACE1 | |
| SCHEMBL3370165 | 0.83 | CASP3 (0.46) | — | |
| SCHEMBL4321426 | 0.83 | BACE1 (0.44) | BACE1BACE2 | |
| SCHEMBL6570634 | 0.80 | OPRD1 (0.57) | OPRD1BACE1BACE2OPRM1OPRK1 | |
| SCHEMBL2168561 | 0.80 | CASP3 (0.41) | BACE1BACE2 | |
| SCHEMBL2383875 | 0.79 | MEN1 (0.47) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29408005 | 0.78 | OPRD1 (0.68) | OPRD1BACE1BACE2OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090098577-A1 | METHOD OF IDENTIFYING COMPOUNDS THAT MODULATE CASPASE 9 ACTIVITY VIA USE OF A KOSMOTROPIC SALT | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090043099-A1 | Methods and compositions for derepression of IAP-inhibited caspase | THE BURNHAM INSTITUTE (US) | 2009-02-12 | — | — | US | disclosed |
| US-7452683-B2 | Identifying enzyme modulators for treating neurodegenerative, autoimmune and tumor diseases | WYETH (US) | 2008-11-18 | — | — | US | disclosed |
| US-7217688-B2 | Methods and compositions for derepression of IAP-inhibited caspase | THE BURNHAM INSTITUTE (US) | 2007-05-15 | — | — | US | disclosed |
| US-20070003535-A1 | Methods and compositions for derepression of IAP-inhibited caspase | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-01-04 | — | — | US | disclosed |
| US-20060258581-A1 | Methods and composition for derepressions of IAP-inhibited caspase | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2006-11-16 | — | — | US | disclosed |
| US-7118877-B2 | Identifying enzyme modulators for treating neurodegenerative, autoimmune and tumor diseases | WYETH (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060211627-A1 | Methods and compositions for derepression of IAP-inhibited caspase | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2006-09-21 | — | — | US | disclosed |
| US-20060211078-A1 | Identifying enzyme modulators for treating neurodegenerative, autoimmune and tumor diseases | WYETH (US) | 2006-09-21 | — | — | US | disclosed |
| EP-1531852-A4 | CASPASE 9 ACTIVATION AND USES THEREFOR | WYETH CORP (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20020183504-A1 | Antibodies to Mch6 polypeptides | THOMAS JEFFERSON UNIVERSITY (US) | 2002-12-05 | — | — | US | disclosed |
| US-6455296-B2 | ISOLATED GENE CODING POLYPEPTIDE | THOMAS JEFFERSON UNIVERSITY | 2002-09-24 | — | — | US | disclosed |
| EP-1161546-A2 | TRANS-SPECIES TRANSFER OF APOPTOTIC GENES AND TRANSGENIC PLANTS DEVELOPED THEREBY | University of Nebraska-Lincoln (US) | 2001-12-12 | — | — | EP | disclosed |
| US-20010016345-A1 | Apoptotic protease Mch6, nucleic acids encoding same and methods of use | ALNEMRI EMAD S (US) | 2001-08-23 | — | — | US | disclosed |
| US-6274318-B1 | DETECTING MODULATORS OF ENZYME ACTIVITY; INCUBATE ENZYMATIC SAMPLE AND INHIBITOR, DETECT REDUCE ACTIVITY FROM ENZYME | THOMAS JEFFERSON UNIVERSITY | 2001-08-14 | — | — | US | disclosed |
| US-6271361-B1 | NUCLEOTIDE SEQUENCES CODING AN ENZYMATIC POLYPEPTIDE; FOR THE TREATMENT OF AUTOIMMUNE AND VIRAL DISEASES, TUMORS AND NERVOUS SYSTEM DISORDERS | THOMAS JEFFERSON UNIVERSITY | 2001-08-07 | — | — | US | disclosed |
| US-20010006779-A1 | APOPTOTIC PROTEASE MCH6, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH, THE | 2001-07-05 | — | — | US | disclosed |
| WO-2000026391-A2 | TRANS-SPECIES TRANSFER OF APOPTOTIC GENES AND TRANSGENIC PLANTS DEVELOPED THEREBY | UNIVERSITY OF NEBRASKA-LINCOLN (US) | 2000-05-11 | — | — | WO | disclosed |
| EP-0765388-A1 | CRYSTAL STRUCTURE AND MUTANTS OF INTERLEUKIN-1BETA(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995035367-A1 | CRYSTAL STRUCTURE AND MUTANTS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258581-A1 | Methods and composition for derepressions of IAP-inhibited caspase | API5, CASP5, CASP7 | OPRD1 4056/4885BACE1 171/4885BACE2 222/4885 |
| US-20060211627-A1 | Methods and compositions for derepression of IAP-inhibited caspase | BIRC5, API5, BIRC3 | OPRD1 4625/4885BACE1 446/4885BACE2 257/4885 |
| US-20070003535-A1 | Methods and compositions for derepression of IAP-inhibited caspase | BIRC5, API5, BIRC3 | OPRD1 4625/4885BACE1 446/4885BACE2 257/4885 |
| US-20090043099-A1 | Methods and compositions for derepression of IAP-inhibited caspase | BIRC5, API5, BIRC3 | OPRD1 4625/4885BACE1 446/4885BACE2 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.